Navigation Links
Advancements in Population Age and Technology Drive Future of Orthopedic Materials Market

NEW YORK, Sept. 26 /PRNewswire/ -- The world orthopedic biomaterials market, valued at $4 billion in 2006, is projected to accelerate in tandem with the world's aging population, reaching $8.8 billion in 2012, according to Orthopedic Biomaterials: World Market, a new report by Kalorama Information.

Changing demographics -- particularly a world population that is expected to include 2 billion individuals aged 60 or older by 2050, improved longevity, and higher quality-of-life expectations -- are driving the number of musculoskeletal conditions being diagnosed and treated across the globe. In Europe, 15-20% of all primary care consultations are for musculoskeletal conditions. In the United States, one out of every seven Americans reports a musculoskeletal impairment.

BMP (bone morphogenetic proteins) products, the newest and fastest growing segment in the orthopedic biomaterials market, are expected to increase their sales and holdings in the market during the forecasted period, growing by a CAGR of 25% to $2.9 billion and accounting for 39% of the market. Ceramic product sales, which accounted for 25% of the market in 2006, are projected to grow at a steady CAGR of 10% between 2006-2012 but account for only 21% of the orthopedic materials market by 2012.

"As a result of evolving technology, a number of biomaterials have been introduced to the market over the past several years, all of which are biologically active substances intended to extend, enhance, or even replace autologous graft," notes Anne Anscomb, the report's author. "However, it is the most recent innovations in the orthopedic biomaterials, the development of recombinant bone morphogenetic proteins (BMPs) and synthetic ceramic products, which show the greatest promise in the quest for the perfect orthopedic biomaterial."

Orthopedic Biomaterials: World Market focuses on products and markets for bone allografts and bone graft substitutes, which include allograft bone substitutes, ceramic-based, polymer-based, factor-based and hyaluronic acid synovial Fluid substitutes. The report analyzes products in development and on the market, leading competitors, and current issues and trends affecting the industry. This report can be purchased directly from Kalorama Information by visiting:

About Kalorama Information

Kalorama Information publishes the latest independent market research on medical markets, including biotechnology, pharmaceuticals, diagnostics, medical devices, and healthcare sectors. For more information, contact Tom Ehart at 240-747-3014 or, or visit


Tom Ehart


SOURCE Kalorama Information
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Liability issues not seen as roadblock to healthcare technology advancements
2. Governor Doyle Pledges Support for Stem Cell Research and Biotechnology Advancements
3. Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System
4. Using the DCode System to Identify DNA Sequence Variation for Studies of Population Structure in Marine Organisms
5. Differential Gene Expression Analysis of Pure Cell Populations from Frozen UterineTissue Using Laser Capture Microdissection (LCM) and cDNA Microarrays
6. Laser Capture Microdissection of muscle fiber populations and expression analysis by RT-PCR
7. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
8. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
9. Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep Technology
10. Novel MicroRNA Array Technology for Sensitive miRNA Profiling
11. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
Post Your Comments:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... STACS DNA Inc., ... Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a Field ... DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further expanding ...
(Date:6/23/2016)... Andrew D Zelenetz ... Published recently in Oncology ... touchONCOLOGY, Andrew D Zelenetz , discusses the ... is placing an increasing burden on healthcare systems ... With the patents on many biologics expiring, interest ...
Breaking Biology Technology:
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):